Evaxion Biotech A/S (EVAX )

Currency in USD Disclaimer
$3.27 +$0.87 (36.25%)
Closed 02/04/2025
$2.93
$4.05
$2.22
$23.7

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol EVAX
  • Company Evaxion Biotech A/S
  • Price $3.27
  • Changes Percentage 36.25
  • Change 0.87
  • Day Low $2.93
  • Day High $4.05
  • Year High $23.7
  • Year Low $2.22
  • Market Cap $1,024,583
  • Price Avg 50 EMA (D) $5.2
  • Price Avg 200 EMA (D) $12.97
  • Exchange NASDAQ
  • Volume 62,638,069
  • Average Volume 1,259,102
  • Open $3.88
  • Previous Close $2.4
  • EPS -14
  • PE -0.23
  • Earnings Announcement 2025-03-25 12:30:00
  • Shares Outstanding $6,266,570

Company brief: EVAXION BIOTECH A/S (EVAX )

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

EVAX Corporation News

Evaxion announces closing of $10.8 million public offering

Evaxion announces closing of $10.8 million public offering

January 31, 2025 at 9:05 pm ET

globenewswire.com -- COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announc...

Income Statement